A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Public ClinicalTrials.gov record NCT00419250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation schedule in subjects with relapsed or refractory B-cell CLL.
Study identification
- NCT ID
- NCT00419250
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 52 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2006 (Actual)
- Primary completion
- Feb 1, 2010 (Actual)
- Completion
- Jun 1, 2010 (Actual)
- Last update posted
- Nov 8, 2019
2006 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Alta Bates Summit Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| Cancer & Blood Disease Center | Lecanto | Florida | 34461 | — |
| Northwest Georgia Oncology Centers, PC., Wellstar Health System | Marietta | Georgia | 30060 | — |
| Mountain States Tumor Institute | Boise | Idaho | 83712 | — |
| Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637-1470 | — |
| Indiana University Medical center | Indianapolis | Indiana | 46202-5149 | — |
| LSU Health Sciences Center, Feist-Weiller Cancer Center | Shreveport | Louisiana | 71130 | — |
| Karmanos Cancer Institute/Wayne State University School of Medicine | Detroit | Michigan | 48201 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Weill Medical College of Cornell University, Division of Hematology & Oncology | New York | New York | 10021 | — |
| SUNY Upstate Medical Center | Syracuse | New York | 13210 | — |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27157 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Abington Hematology Oncology Assoc., Inc. | Willow Grove | Pennsylvania | 19090 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00419250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2019 · Synced Oct 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00419250 live on ClinicalTrials.gov.